AKR1C8P

Across TCGA pan-cancer cohorts, AKR1C8P Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKR1C8P data layer compared with 19 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher AKR1C8P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AKR1C8P expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, STAD, and LAML are the cancer types where AKR1C8P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.561	0.924	<.001	24	view →
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →
LAML	DFS	Median	All	0.081	0.572	.003	12	view →
BLCA	OS	Median	III,IV	0.117	0.684	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.635	.038	4	view →
SKCM	DFS	Median	III,IV	0.835	0.224	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKR1C8P–BRCA (OS)

Open the BRCA breakdown →